Impact of comorbidity, Race, and marital status in men referred for prostate biopsy with PSA >20 ng/mL: A pilot study in high-risk patients

Zachary Klaassen, Roberto Muller, Qiang Li, Alexander J. Tatem, Sherita A. King, Stephen J. Freedland, Rabii Madi, Martha K. Terris, Kelvin A. Moses

Research output: Contribution to journalArticle

Abstract

Objective. To assess the impact of comorbidity, race, and marital status on overall survival (OS) among men presenting for prostate biopsy with PSA >20 ng/mL. Methods. Data were reviewed from 2000 to 2012 and 78 patients were included in the cohort. We analyzed predictors of OS using a Cox proportional hazardsmodel and the association between Charlson Comorbidity Index (CCI) score and PCA diagnosis or high-grade cancer using logistic regression and multinomial regression models, respectively. Results. The median age of patients was 62.5 (IQR 57-73) years.Median CCI was 3 (IQR 2-4), 69% of patients were African American men, 56% of patients were married, and 85% of patients had a positive biopsy. CCI (HR 1.52, 95% CI 1.19, 1.94), PSA (HR 1.62, 95% CI 1.09, 2.42), and Gleason sum (HR 2.04, 95% CI 1.17, 3.56) were associated with OS. CCI was associated with Gleason sum 7 (OR 4.06, 95% CI 1.04, 15.89) and Gleason sum 8-10 (OR 4.52, 95% CI 1.16, 17.54) PCA. Conclusions. CCI is an independent predictor of high-grade disease and worse OS among men with PCA. Race and marital status were not significantly associated with survival in this cohort. Patient comorbidity is an important component of determining the optimal approach to management of prostate cancer.

Original languageEnglish (US)
Article number362814
JournalISRN Urology
Volume2014
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Impact of comorbidity, Race, and marital status in men referred for prostate biopsy with PSA >20 ng/mL: A pilot study in high-risk patients'. Together they form a unique fingerprint.

  • Cite this